Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bone Metastatic Castration-Resistant Prostate Cancer”

107 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 107 results

Testing effectiveness (Phase 2)Study completedNCT02023697
What this trial is testing

Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone

Who this might be right for
Prostatic Neoplasms
Bayer 391
Large-scale testing (Phase 3)Active Not RecruitingNCT02051218
What this trial is testing

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Who this might be right for
Metastatic Breast CancerMetastatic Prostate CancerBone Metastases
Swiss Cancer Institute 1,380
Not applicableStudy completedNCT03223597
What this trial is testing

Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223

Who this might be right for
Prostate Cancer MetastaticBone Metastases
The Netherlands Cancer Institute 300
Testing effectiveness (Phase 2)Study completedNCT03939689
What this trial is testing

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

Who this might be right for
Metastatic Prostate CancerCastration-resistant Prostate CancerProstatic Neoplasm+2 more
Progenics Pharmaceuticals, Inc. 120
Not applicableStudy completedNCT02981797
What this trial is testing

Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223

Who this might be right for
Prostate CancerProstate Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute 10
Testing effectiveness (Phase 2)Study completedNCT01505868
What this trial is testing

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaLymphadenopathy+4 more
M.D. Anderson Cancer Center 170
Not applicableUnknownNCT04833517
What this trial is testing

Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)

Who this might be right for
Prostate Cancer MetastaticCastration Resistant Prostatic CancerAdvanced Prostate Carcinoma
Universität des Saarlandes 500
Testing effectiveness (Phase 2)Ended earlyNCT02964988
What this trial is testing

UPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer MetastaticBone Metastases
Rigshospitalet, Denmark 17
Large-scale testing (Phase 3)Active Not RecruitingNCT02194842
What this trial is testing

Phase III Radium 223 mCRPC-PEACE III

Who this might be right for
Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC 446
Not applicableUnknownNCT01168141
What this trial is testing

Window Study of ZD4054 in Metastatic Prostate Cancer

Who this might be right for
Prostate CancerMetastasis
The Christie NHS Foundation Trust 30
Testing effectiveness (Phase 2)Study completedNCT02601014
What this trial is testing

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

Who this might be right for
Prostate CancerRecurrent Prostate CarcinomaStage IV Prostate Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 32
Testing effectiveness (Phase 2)WithdrawnNCT07025512
What this trial is testing

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

Who this might be right for
Metastatic Castration Resistant Prostate CancerCytopeniaAnemia+1 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT04754425
What this trial is testing

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaCastration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted AgentsMetastatic Malignant Neoplasm in the Bone+5 more
M.D. Anderson Cancer Center 11
Testing effectiveness (Phase 2)Ended earlyNCT03442556
What this trial is testing

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Who this might be right for
ATM Gene MutationBRCA1 Gene MutationBRCA2 Gene Mutation+7 more
University of Washington 18
Early research (Phase 1)Ended earlyNCT03043989
What this trial is testing

Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

Who this might be right for
Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 4
Large-scale testing (Phase 3)WithdrawnNCT00691899
What this trial is testing

Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Who this might be right for
Prostate Cancer
Merck Sharp & Dohme LLC
Testing effectiveness (Phase 2)Study completedNCT01074138
What this trial is testing

Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer

Who this might be right for
Bone-Metastatic, Castration-Resistant Prostate Cancer
Athenex, Inc. 31
Not applicableStudy completedNCT03223727
What this trial is testing

Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223

Who this might be right for
Prostate Cancer MetastaticBone Metastases
The Netherlands Cancer Institute 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT03230734
What this trial is testing

Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 70
Early research (Phase 1)Active Not RecruitingNCT03582475
What this trial is testing

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Who this might be right for
Bladder Small Cell Neuroendocrine CarcinomaCastration-Resistant Prostate CarcinomaMetastatic Bladder Urothelial Carcinoma+14 more
Jonsson Comprehensive Cancer Center 15
Next Page